VYNE Therapeutics Inc. (VYNE) to Distribute Special Dividend of $0.38 on July 23rd

VYNE Therapeutics Inc. (NASDAQ:VYNE) declared a special dividend on Friday, July 10th. Investors of record on Wednesday, July 22nd will be given a dividend of 0.38 per share on Thursday, July 23rd. The ex-dividend date is Wednesday, July 22nd.

VYNE Therapeutics Price Performance

NASDAQ VYNE opened at $0.76 on Monday. VYNE Therapeutics has a 52 week low of $0.28 and a 52 week high of $1.59. The company has a market capitalization of $25.38 million, a P/E ratio of -2.00 and a beta of 2.00. The stock’s 50-day moving average price is $0.67 and its 200-day moving average price is $0.62.

VYNE Therapeutics (NASDAQ:VYNE) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.10. VYNE Therapeutics had a negative return on equity of 70.42% and a negative net margin of 4,726.21%.The company had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.20 million. Research analysts anticipate that VYNE Therapeutics will post -1.1 EPS for the current year.

VYNE Therapeutics Company Profile

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.